These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 22240593)

  • 1. Safety and tolerability of once-daily controlled-release carvedilol 10-80 mg in Japanese patients with chronic heart failure.
    Kitakaze M; Sarai N; Ando H; Sakamoto T; Nakajima H
    Circ J; 2012; 76(3):668-74. PubMed ID: 22240593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adherence with once daily versus twice daily carvedilol in patients with heart failure: the Compliance And Quality of Life Study Comparing Once-Daily Controlled-Release Carvedilol CR and Twice-Daily Immediate-Release Carvedilol IR in Patients with Heart Failure (CASPER) Trial.
    Udelson JE; Pressler SJ; Sackner-Bernstein J; Massaro J; Ordronneau P; Lukas MA; Hauptman PJ
    J Card Fail; 2009 Jun; 15(5):385-93. PubMed ID: 19477398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic profile of controlled-release carvedilol in patients with left ventricular dysfunction associated with chronic heart failure or after myocardial infarction.
    Packer M; Lukas MA; Tenero DM; Baidoo CA; Greenberg BH;
    Am J Cardiol; 2006 Oct; 98(7A):39L-45L. PubMed ID: 17023231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertension.
    Henderson LS; Tenero DM; Baidoo CA; Campanile AM; Harter AH; Boyle D; Danoff TM
    Am J Cardiol; 2006 Oct; 98(7A):17L-26L. PubMed ID: 17023228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beta-receptor selectivity of carvedilol and metoprolol succinate in patients with heart failure (SELECT trial): a randomized dose-ranging trial.
    Zebrack JS; Munger M; Macgregor J; Lombardi WL; Stoddard GP; Gilbert EM
    Pharmacotherapy; 2009 Aug; 29(8):883-90. PubMed ID: 19637941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COMPARE: comparison of the effects of carvedilol CR and carvedilol IR on left ventricular ejection fraction in patients with heart failure.
    Greenberg BH; Mehra M; Teerlink JR; Ordronneau P; McCollum D; Gilbert EM
    Am J Cardiol; 2006 Oct; 98(7A):53L-59L. PubMed ID: 17023233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Long-term outcome and tolerability of carvedilol therapy in Japanese patients with chronic heart failure].
    Kawashiro N; Matsuda N; Endo Y; Uchida Y; Kasanuki H
    J Cardiol; 2006 May; 47(5):229-37. PubMed ID: 16764329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of bisoprolol fumarate compared with carvedilol in Japanese patients with chronic heart failure: results of the randomized, controlled, double-blind, Multistep Administration of bisoprolol IN Chronic Heart Failure II (MAIN-CHF II) study.
    Hori M; Nagai R; Izumi T; Matsuzaki M
    Heart Vessels; 2014 Mar; 29(2):238-47. PubMed ID: 23559359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences between bisoprolol and carvedilol in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized trial.
    Lainscak M; Podbregar M; Kovacic D; Rozman J; von Haehling S
    Respir Med; 2011 Oct; 105 Suppl 1():S44-9. PubMed ID: 22015086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale and design of CASPER: compliance and quality of life study comparing once-daily carvedilol CR and twice-daily carvedilol IR in patients with heart failure.
    Hauptman PJ; Pressler SJ; Sackner-Bernstein J; Ordronneau P; Udelson JE;
    Am J Cardiol; 2006 Oct; 98(7A):60L-66L. PubMed ID: 17023234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma.
    Kotlyar E; Keogh AM; Macdonald PS; Arnold RH; McCaffrey DJ; Glanville AR
    J Heart Lung Transplant; 2002 Dec; 21(12):1290-5. PubMed ID: 12490274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Controlled-release carvedilol in the treatment of essential hypertension.
    Weber MA; Sica DA; Tarka EA; Iyengar M; Fleck R; Bakris GL
    Am J Cardiol; 2006 Oct; 98(7A):32L-38L. PubMed ID: 17023230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a pharmacokinetic/pharmacodynamic model for carvedilol to predict beta1-blockade in patients with congestive heart failure.
    Tenero DM; Henderson LS; Campanile AM; Baidoo CA; Boyle D
    Am J Cardiol; 2006 Oct; 98(7A):27L-31L. PubMed ID: 17023229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose proportionality and pharmacokinetics of carvedilol sustained-release formulation: a single dose-ascending 10-sequence incomplete block study.
    Kim YH; Choi HY; Noh YH; Lee SH; Lim HS; Kim C; Bae KS
    Drug Des Devel Ther; 2015; 9():2911-8. PubMed ID: 26089641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variation in the CYP2D6 genotype is not associated with carvedilol dose changes in patients with heart failure.
    Shihmanter R; Nulman I; Goland S; Caspi A; Bar-Haim A; Harary I; Berkovitch M; Arcavi L
    J Clin Pharm Ther; 2014 Aug; 39(4):432-8. PubMed ID: 24673480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic properties of a new controlled-release formulation of carvedilol.
    Tenero DM; Henderson LS; Baidoo CA; Harter AH; Campanile AM; Danoff TM; Boyle D
    Am J Cardiol; 2006 Oct; 98(7A):5L-16L. PubMed ID: 17023227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolerability of beta-blocker initiation and titration with bisoprolol and carvedilol in congestive heart failure -- a randomized comparison.
    Galatius S; Gustafsson F; Atar D; Hildebrandt PR
    Cardiology; 2004; 102(3):160-5. PubMed ID: 15334027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolerability of carvedilol and ACE-Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN).
    Komajda M; Lutiger B; Madeira H; Thygesen K; Bobbio M; Hildebrandt P; Jaarsma W; Riegger G; Rydén L; Scherhag A; Soler-Soler J; Remme WJ;
    Eur J Heart Fail; 2004 Jun; 6(4):467-75. PubMed ID: 15182773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Titration of carvedilol in elderly heart failure patients.
    Lawless CE; Tamlyn T; Shah R; Karim FM; Khan E; Creech S
    Am J Geriatr Cardiol; 2005; 14(5):230-5. PubMed ID: 16247281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use and risk management of carvedilol for the treatment of heart failure in the community in England: results from a modified prescription-event monitoring study.
    Aurich-Barrera B; Wilton LV; Shakir SA
    Drug Saf; 2009; 32(1):43-54. PubMed ID: 19132804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.